DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactResults

Emcure Pharma Q2FY27 results: Net profit rises 29.31% to ₹325 crore

Business Standard 2 hrs ago·3 Nov 2026, 11:36 am

The company recorded a strong 34 per cent growth in international business to ₹1,665.2 crore during the quarter while its domestic business rose 11.1 per cent to ₹1,155.3 crore

Affected stocks

Bullish1 stock

Emcure Pharmaceuticals L

EMCURE Bullish

₹1,883.50

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Emcure Pharmaceuticals L (EMCURE).
Category: Results.
AI reads the tone as positive (potentially bullish) for the stock.
Assessed as a significant, market-relevant update.

Why it matters

A meaningful update for Emcure Pharmaceuticals L worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Business Standard.